CVBT Closes Clinical Development Agreement for Coronary Heart Disease Drug Candidate
Posted on: Thursday, 13 November 2008, 09:00 CST
LAS VEGAS, Nov. 13 /PRNewswire-FirstCall/ -- CardioVascular BioTherapeutics, Inc. (BULLETIN BOARD: CVBT) (the "Company") has entered into its first clinical development agreement for its Coronary Heart Disease drug candidate with Cardio Neo-Genesis, LP ("CNG"). The agreement, dated November 11, 2008 states that CNG can fund up to $15,000,000 of the clinical development for the Company's Coronary Heart Disease (CHD) drug candidate. The agreement also provides for a royalty to CNG payable from 5% of CVBT's cash-flow stream on its CHD drug up to 20 times return to CNG's limited partners.
"CVBT is currently utilizing clinical development agreements to fund and advance our drug development candidates," according to Mr. Mickael A. Flaa, CVBT's Chief Financial Officer. Mr. Flaa continued, "Given the stress in the financial markets at this time, we looked to the lessons of history for a strategy to finance CVBT's drug development program. The clinical development arrangements that CVBT has entered into are similar in structure to those used successfully by Amgen, Genentech, Biogen, and others over 20 years ago to fund their drug development programs."
"This development agreement is a positive step in advancing CVBT's CHD drug candidate given today's financial markets," said Mr. Daniel C. Montano, CVBT's CEO. Mr. Montano continued, "I believe that CVBT's existing shareholders will benefit from this new source of funding which does not permanently dilute their shareholdings."
About CardioVascular BioTherapeutics
CVBT (OTCBB: CVBT) is a biopharmaceutical company developing human FGF-1 for cardiovascular diseases characterized by inadequate blood flow to a tissue or organ. In addition to the Phase II trial it is conducting in patients with severe coronary heart disease, the company has two FDA-authorized clinical trials in the areas of impaired wound healing seen in diabetics and in patients suffering from peripheral artery disease of the legs. An additional study is being conducted in patients with chronic back pain who may have perfusion defects to their spine. For more information about CardioVascular BioTherapeutics, Inc. please visit http://www.cvbt.com/.
CardioVascular BioTherapeutics, Inc. Allison Caplan, (702) 839-7200 acaplan@cvbt.com
CardioVascular BioTherapeutics, Inc.
CONTACT: Allison Caplan of CardioVascular BioTherapeutics, Inc.,+1-702-839-7200, acaplan@cvbt.com
Web Site: http://www.cvbt.com/
Source: PRNewswire-FirstCall
Related Articles
- New Consortium to Develop Drugs for Neglected Tropical Diseases
- Alzheimer's Drug Discovery Foundation Funds PharmatrophiX to Develop Drugs to Prevent Neurodegenerative Disease
- CardioVascular BioTherapeutics to Present at Wall Street Analyst Forum on September 20
- BusinessWeek Article Highlights CardioVascular BioTherapeutics for Developing a Promising Protein Therapy to Treat Coronary Artery Disease
- CardioVascular BioTherapeutics Initiates Study on the Treatment of Peripheral Artery Disease
- CardioVascular BioTherapeutics Appoints Mike Norris Vice President of Business Development
- CardioVascular BioTherapeutics Signs Agreement With Kendle for Phase II Clinical Trial
- CardioVascular BioTherapeutics Engages The Bruckner Group to Evaluate Healthcare Value Proposition of Drug Candidates
- CardioVascular BioTherapeutics Co-Founder to Present Seminar on New Treatment for Heart Disease; Renowned Cardiac & Thoracic Surgeon Dr. Thomas Stegmann to Introduce Novel Protein Drug Candidate
- CardioVascular BioTherapeutics, Inc. Announces Initiation of Clinical Studies to Treat Patients With Chronic Back Pain
 |
 |
User Comments (0)
RSS Feeds